OnKure Therapeutics, Inc.
$4.99
▲
5.41%
2026-04-21 08:37:00
onkuretherapeutics.com
NGM: OKUR
Explore OnKure Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$68.37 M
Current Price
$4.99
52W High / Low
$5.06 / $1.7
Stock P/E
—
Book Value
$4.11
Dividend Yield
—
ROCE
-112.02%
ROE
-74.39%
Face Value
—
EPS
$-4.4
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
45
Beta
—
Debt / Equity
0.98
Current Ratio
10.28
Quick Ratio
10.28
Forward P/E
-2.09
Price / Sales
—
Enterprise Value
$0.3 M
EV / EBITDA
-0.01
EV / Revenue
—
Rating
Strong Buy
Target Price
$20.2
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aktis Oncology, Inc. | $20.83 | — | $1.08 B | — | -31.96% | -29.45% | $29.16 / $14.72 | $-159.68 |
| 2. | Upstream Bio, Inc. | $9.99 | — | $543.66 M | — | -47.12% | -35.44% | $33.68 / $7.25 | $6.26 |
| 3. | Evaxion A/S | $4.49 | — | $37.11 M | — | -38.23% | -1% | $12.15 / $1.25 | $2.04 |
| 4. | Protalix BioTherapeutics, Inc. | $2.27 | — | $184.11 M | — | -9.85% | -14.44% | $3.19 / $1.32 | $0.6 |
| 5. | Insmed Incorporated | $143.43 | — | $31.02 B | — | -55.4% | -2.49% | $212.75 / $63.81 | $3.45 |
| 6. | Karyopharm Therapeutics Inc. | $8.94 | — | $193.06 M | — | -554.58% | 81.86% | $10.99 / $3.65 | $-16 |
| 7. | GridAI Technologies Corp. | $2.79 | — | $9.38 M | — | -27% | -58.82% | $5.84 / $0.97 | — |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -14.12 M | -15.5 M | -16.32 M | -17 M | -33.8 M | — |
| Net Profit | -13.5 M | -14.7 M | -15.39 M | -15.93 M | -35.19 M | — |
| EPS in Rs | -0.99 | -1.07 | -1.13 | -1.16 | -2.57 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -62.95 M | -54.39 M | -36.93 M | -29.77 M |
| Net Profit | -59.52 M | -52.67 M | -35.31 M | -29.51 M |
| EPS in Rs | -4.35 | -3.85 | -2.58 | -2.16 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 62.12 M | 114.91 M | 35.73 M | 16 M |
| Total Liabilities | 5.93 M | 11.08 M | 137.58 M | 70.42 M |
| Equity | 56.18 M | 103.83 M | -101.84 M | -54.42 M |
| Current Assets | 60.84 M | 113 M | 33.77 M | 13.62 M |
| Current Liabilities | 5.92 M | 10.53 M | 7.29 M | 5.54 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -51.83 M | -51.12 M | -34.55 M | -26.95 M |
| Investing CF | -0.05 M | 15.87 M | -0.25 M | -1.13 M |
| Financing CF | 0.16 M | 116.13 M | 53.12 M | 26.46 M |
| Free CF | -51.87 M | -51.17 M | -34.79 M | -28.09 M |
| Capex | -0.05 M | -0.05 M | -0.25 M | -1.13 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -12.99% | -49.17% | -19.65% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-10-07 | 1:0.1 |